Risks Downplayed As Boston Scientific Nears Guidant Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific claims it can handle the debt it will incur from its approximately $28 bil. acquisition of Guidant and that it has the history to prove it